Danaher Corp.
Danaher Corporation (DHR) is a diversified science and technology company focused on life sciences, diagnostics and environmental & applied solutions. It supplies instruments, consumables, software and services used by research laboratories, hospitals and industrial customers worldwide. With a market capitalisation of about $155.94 billion, Danaher combines organic R&D-driven growth with disciplined acquisitions and operational rigor (the Danaher Business System) to drive recurring revenue and margin expansion. Investors often watch its exposure to healthcare spending, diagnostic cycles and capital-equipment demand. Strengths include a broad product portfolio, strong cash generation and a track record of integrating acquisitions; risks include execution on M&A, regulatory changes, cyclicality in capital spending and currency swings. Valuation can be premium given its defensive characteristics, but future returns are uncertain. This is general educational information, not personal investment advice — consider your goals and consult an authorised adviser before making investment decisions.
Why It's Moving
Danaher Stock Eyes 27% Upside as Analysts Bet on Life Sciences Recovery and Margin Expansion in 2026
- Q4 beat on earnings and revenue with adjusted EPS of $2.23 and $1.8 billion in free cash flow, despite CEO Rainer Blair's cautious 2026 outlook of 3-6% core revenue growth and $8.35-$8.50 adjusted EPS
- Life sciences weakness and academic funding headwinds prompted the market pullback, but respiratory revenue stabilization at $1.8 billion forecast for 2026 suggests demand normalization is underway
- Analysts project a $272 price target for year-end 2026, implying 27.9% upside from current levels, with gains anchored by recurring consumables strength and operational leverage rather than aggressive valuation expansion
Danaher Stock Eyes 27% Upside as Analysts Bet on Life Sciences Recovery and Margin Expansion in 2026
- Q4 beat on earnings and revenue with adjusted EPS of $2.23 and $1.8 billion in free cash flow, despite CEO Rainer Blair's cautious 2026 outlook of 3-6% core revenue growth and $8.35-$8.50 adjusted EPS
- Life sciences weakness and academic funding headwinds prompted the market pullback, but respiratory revenue stabilization at $1.8 billion forecast for 2026 suggests demand normalization is underway
- Analysts project a $272 price target for year-end 2026, implying 27.9% upside from current levels, with gains anchored by recurring consumables strength and operational leverage rather than aggressive valuation expansion
When is the next earnings date for Danaher Corp. (DHR)?
Danaher's next earnings report is estimated to be released in late April 2026, with sources indicating a target date between April 21 and April 28, 2026. The company has not yet officially confirmed the precise date, though this timing aligns with its historical earnings release schedule. This announcement will cover Q1 2026 results, with analysts projecting earnings per share of $1.94. Investors should monitor Danaher's investor relations website for official confirmation of the exact earnings date and conference call time.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Danaher’s stock with a target price of $259.6, indicating strong potential for growth.
Financial Health
Danaher Corp. shows strong revenue and profits, indicating solid financial performance overall.
Dividend
Danaher Corp.'s low dividend yield of 0.52% indicates limited returns from dividends. If you invested $1000 you would be paid $5.20 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring DHR
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketActivist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: August 11, 2025
Explore BasketAcquirer's Engine
Invest in companies with proven expertise in growth-by-acquisition. These carefully selected stocks represent businesses with exceptional management teams that consistently buy their way to market leadership and enhanced profitability through strategic M&A.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Revenue Engine
Consumables and service contracts support predictable recurring revenue and cash flow, though demand can vary with spending cycles.
Global Healthcare Reach
A broad international footprint offers diversification across markets, while currency moves and regional regulation remain potential headwinds.
Innovation & M&A
R&D and targeted acquisitions expand capabilities and addressable markets, but integration and valuation risks deserve attention.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Abbott Laboratories
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
Agilent Technologies Inc.
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
Align Technology Inc.
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
